Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Expanded Access Study of NeuroVax for Multiple Sclerosis Patients

Next Previous
Trial Profile

An Expanded Access Study of NeuroVax for Multiple Sclerosis Patients

Status: Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 26 Apr 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IR 902 (Primary)
  • Indications Multiple sclerosis
  • Focus Expanded access; Therapeutic Use

Most Recent Events

  • 26 Apr 2019 New trial record
  • 23 Apr 2019 According to an Immune Response BioPharma media release, the company expects that robust patients may only enroll via Immune Response Website: IRBP.It changed compensation to unlimited income per patient per injection no cap: patient will receive vaccine and payment for 500 patients enrolled. Once study enrollment is reached no additional patients will be allowed to participate due to low supply of vaccine.
  • 23 Apr 2019 According to an Immune Response BioPharma media release, the company expects NeuroVax to be oversubscribed right to try, enrollment picking up steam.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top